Jazz Pharmaceuticals plc cotiza a 210.39 USD y tiene una capitalización bursátil de $13.7B. En los últimos 12 meses ha facturado $4.6B con un margen de flujo de caja libre del 30.4%. Cotiza a 8.6 veces su flujo de caja libre (P/FCF) y a un PER de 14.5. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Ga…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $5.71 | $6.34 | $6.64 |
| Estimado | $3.04 | $6.18 | $4.66 | $6.51 |
| Sorpresa | — | -7.6% | +36.1% | +2.0% |
| Métrica | JAZZ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -10.1% | -38.6% | +28.5% |
| Net Margin | -8.3% | -33.6% | +25.2% |
| FCF Margin | 30.4% | -13.9% | +44.3% |
| ROE | -8.3% | -40.4% | +32.1% |
| ROA | -3.0% | -32.0% | +29.0% |
| Current Ratio | 1.86 | 2.84 | -0.98 |
| Debt / Equity | 1.24 | 0.28 | +0.96 |